GlaxoSmithKline has announced that the FDA has approved fluticasone furoate inhalation powder, as a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as preventative therapy in patients 12 and up. This therapy is only intended to prevent an asthma attack, not to treat it once it happens. For treating an asthma attack, one[…]
FDA Approves Fluticasone Furoate for Once-Daily Asthma Therapy
Anti-Asthma / COPD, Drug Research & Development API, FDA Approved 2014, Respiratory Tract Agent Tags: asthma Aug 27, 2014
Esomeprazole 24 Hour Now OTC
Anti-ulcerant, Drug Research & Development API, Gastrointestinal Agent, OTC and Compounding Product Tags: asthmaproton pump inhibitor Apr 24, 2014
The recent FDA approval for AstraZeneca’s Nexium 24 hour, or Esomeprazole, was exciting news for the pharmaceutical world. With over sixty million Americans suffering from heartburn at least once a month the advent of a 24 hour treatment that is easy to access is relieving. As an OTC or over the counter treatment for gastroesophageal[…]
Desloratadine is Still Effectual and Tolerable for Allergy Sufferers
OTC and Compounding Product, TEVA API Tags: asthma Feb 07, 2014
Known as the brand name Clarinex, as well as Clarinex D 12 Hour, Desloratadine is a steadfast and tolerable treatment for allergies. Desloratadine offers anti-inflammatory benefits, as it is a selective H(1)-receptor antagonist. Known as a safe and effective antihistamine for both adults and children, it comes as no surprise that IMS Health released positive[…]
Fluticasone Propionate Receives NDA but Remains in Short Supply
Anti-Asthma / COPD, Drug Research & Development API, NDA, OTC and Compounding Product Tags: asthma Nov 18, 2013
Fluticasone Propionate, which is currently short in supply, received a New Drug Application, or NDA at on July 31, 2013. Drug maker Perrigo announced the new drug application for fluticasone propionate lotion, 0.05%. This form of fluticasone propionate lotion is the generic equivalent to Cutivate Lotion, 0.05%. The use of the effectual and tolerable corticosteroid[…]
FDA Approves New Drug Application for Carbinoxamine
Analgesic, Anti-Inflammatory Tags: allergic conjunctivitisasthmaNew Drug Application Apr 11, 2013
On April 3, 2013 the FDA approved the new drug application carbinoxamine maleate, CAS number 3505-38-2, for the treatment of allergic rhinitis. Targeted for patients suffering from seasonal and perennial allergic rhinitis, the approval of carbinoxamine is a novel approach to allergy relief. Carbinoxamine is the first sustained-release histamine receptor blocking agent that is indicated[…]
FDA Approves New Indication for Budesonide
Anti-Asthma / COPD, Anti-Inflammatory, Bulk Active Ingredient, Drug Research & Development API, OTC and Compounding Product, Patent Expiration 2017 Tags: asthma Feb 18, 2013
On January 15, 2013 Santarus, Inc. announced that the FDA had approved Budesonide, as the brand name Ulceris, for the induction of remission in patients with mild, moderate and active forms of ulcerative colitis. As an extended release tablet, this new indication approval of budesonide is a vital and novel therapeutic option for patients. Adult[…]
COPD Patients Can Breathe Easier with Indacaterol
Anti-Asthma / COPD, FDA Approved 2011, Respiratory Tract Agent Tags: asthmaCOPD Dec 27, 2012
On July 5, 2011, Indacaterol was approved by the FDA for the treatment of chronic obstructive pulmonary disease, or COPD. Novartis announced that the brand name for this device would be the Arcapta Neohaler, and the specific approval for this once daily medication is as a long-acting beta2-adrenergic agonist for the maintenance treatment of airflow[…]
A Trio of Uses for Mometasone Furoate
Anti-Asthma / COPD, Bulk Active Ingredient, Patent Expiration 2014, Respiratory Tract Agent, TEVA API Tags: asthma Jun 18, 2012
Mometasone Furoate, CAS# 83919-23-7 is in the class of drugs known as corticosteroids, there are several products in which mometasone furoate is efficacious. For the treatment of asthma, mometasone furoate may also be known by the brand name Asmanex Twisthaler. Offered in powder form, inhalation 110 mcg/actuation or 220 mcg/actuation, mometasone furoate relieves asthmatic symptoms[…]
Tranilast – Asthma Drug Shows Promise for Treating Breast Cancer
Anti-Asthma / COPD, Chemotherapeutic / Anti-Neoplastic Tags: asthmabreast cancer Dec 03, 2010
LGM Pharma is a US based supplier of the API (Active Pharmaceutical Ingredient) Tranilast CAS# 53902-12-8 for research and development purposes. Tranilast CAS# 53902-12-8 (a drug in current use for treatment of asthma) has performed well in a pre-clinical trial as a potential chemotherapy agent for breast cancer. The drug, tranilast, has been approved since[…]
